Novartis (NVS) Issues Quarterly Earnings Results, Beats Expectations By $0.03 EPS

Novartis (NYSE:NVS) released its earnings results on Thursday. The company reported $1.28 EPS for the quarter, topping the consensus estimate of $1.25 by $0.03, Morningstar.com reports. Novartis had a return on equity of 16.18% and a net margin of 16.04%. The business had revenue of $12.69 billion during the quarter, compared to analysts’ expectations of $12.45 billion. During the same quarter last year, the firm posted $1.13 earnings per share. The firm’s revenue was up 10.0% on a year-over-year basis.

Shares of NYSE:NVS opened at $77.88 on Friday. The company has a market capitalization of $183,079.03, a price-to-earnings ratio of 16.19, a PEG ratio of 1.79 and a beta of 0.74. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.91 and a current ratio of 1.21. Novartis has a 52-week low of $73.31 and a 52-week high of $94.19.

How to Become a New Pot Stock Millionaire

Large investors have recently made changes to their positions in the business. Pinnacle Wealth Planning Services Inc. bought a new position in Novartis in the fourth quarter worth approximately $113,000. Calton & Associates Inc. bought a new position in Novartis in the fourth quarter worth approximately $118,000. SeaCrest Wealth Management LLC bought a new position in Novartis in the fourth quarter worth approximately $124,000. Trustcore Financial Services LLC bought a new position in Novartis in the fourth quarter worth approximately $178,000. Finally, Sawyer & Company Inc bought a new position in Novartis in the fourth quarter worth approximately $183,000. Institutional investors and hedge funds own 10.76% of the company’s stock.

Several research firms recently commented on NVS. Deutsche Bank reaffirmed a “neutral” rating on shares of Novartis in a research note on Friday. JPMorgan Chase reaffirmed a “neutral” rating on shares of Novartis in a research note on Monday, April 9th. Nord/LB reaffirmed a “neutral” rating on shares of Novartis in a research note on Tuesday, January 2nd. UBS reaffirmed a “neutral” rating on shares of Novartis in a research note on Monday, January 15th. Finally, Zacks Investment Research cut Novartis from a “hold” rating to a “sell” rating in a research note on Tuesday, January 2nd. Four investment analysts have rated the stock with a sell rating, eight have issued a hold rating and one has given a buy rating to the company. Novartis currently has a consensus rating of “Hold” and a consensus target price of $87.51.

COPYRIGHT VIOLATION NOTICE: “Novartis (NVS) Issues Quarterly Earnings Results, Beats Expectations By $0.03 EPS” was posted by Week Herald and is owned by of Week Herald. If you are reading this article on another website, it was illegally copied and republished in violation of international trademark and copyright laws. The original version of this article can be read at https://weekherald.com/2018/04/21/novartis-nvs-issues-quarterly-earnings-results-beats-expectations-by-0-03-eps.html.

Novartis Company Profile

Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segment also commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines.

Earnings History for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply